Medical News

---

• Comorbid OCD and bipolar disorder should be treated as mood disorder
• Advanced age should not preclude sunitinib use for mRCC
• Altering sunitinib dosing schedule improves tolerability
• Factors predicting disengagement from psychosis early intervention identified
• Comorbid OCD and bipolar disorder should be treated as mood disorder
• Factors predicting disengagement from psychosis early intervention identified
• Advanced age should not preclude sunitinib use for mRCC
• Altering sunitinib dosing schedule improves tolerability

Comorbid OCD and bipolar disorder should be treated as mood disorder Posted: 20 Feb 2014 04:00 PM PST Most patients with both bipolar disorder and obsessive–compulsive disorder should be treated as having bipolar disorder, researchers suggest.

Advanced age should not preclude sunitinib use for mRCC Posted: 20 Feb 2014 04:00 PM PST Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows.

Altering sunitinib dosing schedule improves tolerability Posted: 20 Feb 2014 04:00 PM PST Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug's overall tolerability without affecting its efficacy, say Japanese researchers.

Factors predicting disengagement from psychosis early intervention identified Posted: 20 Feb 2014 04:00 PM PST A study of first-episode psychosis patients in Hong Kong has found that those with fewer negative symptoms at presentation and poor medication compliance were more likely than others to disengage from an early intervention program.

Comorbid OCD and bipolar disorder should be treated as mood disorder Posted: 20 Feb 2014 04:00 PM PST Most patients with both bipolar disorder and obsessive–compulsive disorder should be treated as having bipolar disorder, researchers suggest.

Factors predicting disengagement from psychosis early intervention identified Posted: 20 Feb 2014 04:00 PM PST A study of first-episode psychosis patients in Hong Kong has found that those with fewer negative symptoms at presentation and poor medication compliance were more likely than others to disengage from an early intervention program.

Advanced age should not preclude sunitinib use for mRCC Posted: 20 Feb 2014 04:00 PM PST Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows.

Altering sunitinib dosing schedule improves tolerability Posted: 20 Feb 2014 04:00 PM PST Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug's overall tolerability without affecting its efficacy, say Japanese researchers.

You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610